Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms

Journal of Immunology

Volumn 193, Issue 10, 2014, Pages 4823-4832

  Chen, Ding ^a   Blazek, Monica ^a   Ireland, Sara ^a   Ortega, Sterling ^a   Kong, Xiangmei ^a   Meeuwissen, Anouk ^a   Stowe, Ann ^a   Carter, Laura ^b   Wang, Yue ^b   Herbst, Ronald ^b   Monson, Nancy L ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MEDIMMUNE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIBODY; CD1D ANTIGEN; CD5 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17; MYELIN; SYNDECAN 1; TRANSCRIPTION FACTOR FOXP3; ANTIBODY; CD19 ANTIGEN; CD1D ANTIGEN, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BIOENGINEERING; BONE MARROW; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; IMMUNOREACTIVITY; IMMUNOREGULATION; MALE; MOUSE; NONHUMAN; PLASMA CELL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; SPINAL CORD; TREATMENT OUTCOME; ANIMAL; CELL SURVIVAL; CHEMICALLY INDUCED; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LYMPHOCYTE DEPLETION; PATHOLOGY; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION; SPLEEN; TRANSGENIC MOUSE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES; ANTIGENS, CD19; ANTIGENS, CD1D; B-LYMPHOCYTES, REGULATORY; BONE MARROW; CELL SURVIVAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, TRANSGENIC; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PLASMA CELLS; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION; SPINAL CORD; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 84910150823     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401478     Document Type: Article

References (46)

1. Frohman, E. M., M. K. Racke, and C. S. Raine. 2006. Multiple sclerosis-The plaque and its pathogenesis. N. Engl. J. Med. 354: 942-955.
2. Ireland, S., and N. Monson. 2011. Potential impact of B cells on T cell function in multiple sclerosis. Mult. Scler. Int. 2011: 423971.
3. Weber, M. S., B. Hemmer, and S. Cepok. 2011. The role of antibodies in multiple sclerosis. Biochim. Biophys. Acta 1812: 239-245.
4. Krumbholz, M., T. Derfuss, R. Hohlfeld, and E. Meinl. 2012. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat. Rev. Neurol. 8: 613-623.
5. Lyons, J. A., M. J. Ramsbottom, and A. H. Cross. 2002. Critical role of antigenspecific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. Eur. J. Immunol. 32: 1905-1913.
6. Lyons, J. A., M. San, M. P. Happ, and A. H. Cross. 1999. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur. J. Immunol. 29: 3432-3439.
7. Lassmann, H., C. Brunner, M. Bradl, and C. Linington. 1988. Experimental allergic encephalomyelitis: The balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions. Acta Neuropathol. 75: 566-576.
8. Linington, C., M. Bradl, H. Lassmann, C. Brunner, and K. Vass. 1988. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 130: 443-454.
9. Lehmann-Horn, K., H. C. Kronsbein, and M. S. Weber. 2013. Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther. Adv. Neurol. Disord. 6: 161-173.
10. Anderton, S. M., and S. Fillatreau. 2008. Activated B cells in autoimmune diseases: The case for a regulatory role. Nat. Clin. Pract. Rheumatol. 4: 657-666.
11. Hartung, H. P., and B. C. Kieseier. 2010. Atacicept: Targeting B cells in multiple sclerosis. Ther. Adv. Neurol. Disord. 3: 205-216.
12. Kappos, L., H. P. Hartung, M. S. Freedman, A. Boyko, E. W. Radü, D. D. Mikol, M. Lamarine, Y. Hyvert, U. Freudensprung, T. Plitz, and J. van Beek, ATAMS Study Group. 2014. Atacicept in multiple sclerosis (ATAMS): A randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 13: 353-363.
13. Hoffmann, F., and E. Meinl. 2014. B cells in multiple sclerosis: good or bad guys?: An article for 28 May 2014 -World MS Day 2014. Eur. J. Immunol. 44: 1247-1250.
14. Yazawa, N., Y. Hamaguchi, J. C. Poe, and T. F. Tedder. 2005. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl. Acad. Sci. USA 102: 15178-15183.
15. Herbst, R., Y. Wang, S. Gallagher, N. Mittereder, E. Kuta, M. Damschroder, R. Woods, D. C. Rowe, L. Cheng, K. Cook, et al. 2010. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J. Pharmacol. Exp. Ther. 335: 213-222.
16. Matsushita, T., K. Yanaba, J. D. Bouaziz, M. Fujimoto, and T. F. Tedder. 2008. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118: 3420-3430.
17. DiLillo, D. J., Y. Hamaguchi, Y. Ueda, K. Yang, J. Uchida, K. M. Haas, G. Kelsoe, and T. F. Tedder. 2008. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J. Immunol. 180: 361-371.
18. Hao, J., R. Liu, W. Piao, Q. Zhou, T. L. Vollmer, D. I. Campagnolo, R. Xiang, A. La Cava, L. Van Kaer, and F. D. Shi. 2010. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 207: 1907-1921.
19. Maddur, M. S., P. Miossec, S. V. Kaveri, and J. Bayry. 2012. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am. J. Pathol. 181: 8-18.
20. Duhen, R., S. Glatigny, C. A. Arbelaez, T. C. Blair, M. Oukka, and E. Bettelli. 2013. Cutting edge: The pathogenicity of IFN-γ-producing Th17 cells is independent of T-bet. J. Immunol. 190: 4478-4482.
21. Rao, P., and B. M. Segal. 2012. Experimental autoimmune encephalomyelitis. Methods Mol. Biol. 900: 363-380.
22. Lovett-Racke, A. E., Y. Yang, and M. K. Racke. 2011. Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis? Biochim. Biophys. Acta 1812: 246-251.
23. Stromnes, I. M., L. M. Cerretti, D. Liggitt, R. A. Harris, and J. M. Goverman. 2008. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat. Med. 14: 337-342.
24. Fletcher, J. M., S. J. Lalor, C. M. Sweeney, N. Tubridy, and K. H. Mills. 2010. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162: 1-11.
25. Shevach, E. M. 2009. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30: 636-645.
26. Mills, K. H. 2004. Regulatory T cells: friend or foe in immunity to infection? Nat. Rev. Immunol. 4: 841-855.
27. Jäger, A., and V. K. Kuchroo. 2010. Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand. J. Immunol. 72: 173-184.
28. Serada, S., M. Fujimoto, M. Mihara, N. Koike, Y. Ohsugi, S. Nomura, H. Yoshida, T. Nishikawa, F. Terabe, T. Ohkawara, et al. 2008. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 105: 9041-9046.
29. Fujimoto, M., M. Nakano, F. Terabe, H. Kawahata, T. Ohkawara, Y. Han, B. Ripley, S. Serada, T. Nishikawa, A. Kimura, et al. 2011. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J. Immunol. 186: 32-40.
30. Barr, T. A., P. Shen, S. Brown, V. Lampropoulou, T. Roch, S. Lawrie, B. Fan, R. A. O'Connor, S. M. Anderton, A. Bar-Or, et al. 2012. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 209: 1001-1010.
31. Molnarfi, N., U. Schulze-Topphoff, M. S. Weber, J. C. Patarroyo, T. Prod'homme, M. Varrin-Doyer, A. Shetty, C. Linington, A. J. Slavin, J. Hidalgo, et al. 2013. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J. Exp. Med. 210: 2921-2937.
32. Flores-Borja, F., A. Bosma, D. Ng, V. Reddy, M. R. Ehrenstein, D. A. Isenberg, and C. Mauri. 2013. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci. Transl. Med. 5: 173ra123.
33. Carter, N. A., R. Vasconcellos, E. C. Rosser, C. Tulone, A. Muñoz-Suano, M. Kamanaka, M. R. Ehrenstein, R. A. Flavell, and C. Mauri. 2011. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J. Immunol. 186: 5569-5579.
34. McNally, A., G. R. Hill, T. Sparwasser, R. Thomas, and R. J. Steptoe. 2011. CD4+ CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis. Proc. Natl. Acad. Sci. USA 108: 7529-7534.
35. Ray, A., S. Basu, C. B. Williams, N. H. Salzman, and B. N. Dittel. 2012. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J. Immunol. 188: 3188-3198.
36. + regulatory T cells proceeds normally in the absence of B cells during EAE. Eur. J. Immunol. 42: 1164-1173.
37. Watanabe, R., N. Ishiura, H. Nakashima, Y. Kuwano, H. Okochi, K. Tamaki, S. Sato, T. F. Tedder, and M. Fujimoto. 2010. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J. Immunol. 184: 4801-4809.
38. Gong, Q., Q. Ou, S. Ye, W. P. Lee, J. Cornelius, L. Diehl, W. Y. Lin, Z. Hu, Y. Lu, Y. Chen, et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174: 817-826.
39. Hamel, K., P. Doodes, Y. Cao, Y. Wang, J. Martinson, R. Dunn, M. R. Kehry, B. Farkas, and A. Finnegan. 2008. Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J. Immunol. 180: 4994-5003.
40. Yang, M., K. Rui, S. Wang, and L. Lu. 2013. Regulatory B cells in autoimmune diseases. Cell. Mol. Immunol. 10: 122-132.
41. Heidt, S., J. Hester, S. Shankar, P. J. Friend, and K. J. Wood. 2012. B cell repopulation after alemtuzumab induction-Transient increase in transitional B cells and long-Term dominance of naive B cells. Am. J. Transplant. 12: 1784-1792.
42. Tedder, T. F. 2009. CD19: A promising B cell target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5: 572-577.
43. Mei, H. E., S. Schmidt, and T. Dörner. 2012. Rationale of anti-CD19 immunotherapy: An option to target autoreactive plasma cells in autoimmunity. Arthritis Res. Ther. 14(Suppl. 5): S1.
44. Wang, W., J. Rangel-Moreno, T. Owen, J. Barnard, S. Nevarez, H. T. Ichikawa,and J. H. Anolik. 2014. Long-Term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche. J. Immunol. 192: 3011-3020.
45. Bansal, P., T. Khan, U. Bussmeyer, D. K. Challa, R. Swiercz, R. Velmurugan, R. J. Ober, and E. S. Ward. 2013. The encephalitogenic, human myelin oligodendrocyte glycoprotein-induced antibody repertoire is directed toward multiple epitopes in C57BL/6-immunized mice. J. Immunol. 191: 1091-1101.
46. Challa, D. K., U. Bussmeyer, T. Khan, H. P. Montoyo, P. Bansal, R. J. Ober, and E. S. Ward. 2013. Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis. MAbs 5: 655-659.